WO1997003185A1 - Production de proteines a l'aide de bacillus incapable de sporuler - Google Patents

Production de proteines a l'aide de bacillus incapable de sporuler Download PDF

Info

Publication number
WO1997003185A1
WO1997003185A1 PCT/DK1996/000304 DK9600304W WO9703185A1 WO 1997003185 A1 WO1997003185 A1 WO 1997003185A1 DK 9600304 W DK9600304 W DK 9600304W WO 9703185 A1 WO9703185 A1 WO 9703185A1
Authority
WO
WIPO (PCT)
Prior art keywords
mutation
sporulation
bacterium
licheniformis
subtilis
Prior art date
Application number
PCT/DK1996/000304
Other languages
English (en)
Inventor
Fergus G. Priest
Alastair B. Fleming
Martin Tangney
Per Linå JØRGENSEN
Børge DIDERICHSEN
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Priority to JP9505426A priority Critical patent/JPH11509096A/ja
Priority to EP96922780A priority patent/EP0837925A1/fr
Priority to AU63538/96A priority patent/AU6353896A/en
Publication of WO1997003185A1 publication Critical patent/WO1997003185A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus
    • C12R2001/075—Bacillus thuringiensis

Definitions

  • the present invention relates to a process for the production of various products, especially translocated polypeptides by using bacteria of the genus Bacillus which have been mutated to be incapable of sporulation, methods for producing such bacteria, and DNA constructs to be used in the processes.
  • Bacteria of the genus Bacill us are being used in the production of various polypeptides and proteins for use in medicine and various industries.
  • Bacillus licheniformis is used exten ⁇ sively for the production of industrial enzymes such as amylase and protease and is a popular host for the industrial prepara ⁇ tion of cloned gene products (1, 2, 3) .
  • industrial enzymes such as amylase and protease
  • Hundreds of tons of extracellular enzymes are manufactured annually from this orga ⁇ nism resulting in the need to dispose of a considerable tonnage of spent organisms, usually as composts.
  • the first morphological change observed during the sporulation process is the synthesis of an asymmetric septum at stage II.
  • Gene expression in the mother cell and maturing spore is partly governed by the ordered synthesis and activation of a cascade of sigma factors, which direct RNA polymerase to transcribe sporulation specific promoters in a temporally and spatially oriented fashion (4, 5) .
  • the ⁇ F protein the product of the spoIIAC gene (8, 9) is one such sigma factor which is present in the predivisional cell but its activity is restricted to the prespore and only becomes evident after septation (14) .
  • This sigma factor is crucial for establishment of compartment-specific gene expression (10) and, without it, expression of numerous genes in the developing spore is prevented.
  • a major function of ⁇ F is activation of expression of the prespore specific sigma factor ⁇ G , which is responsible for gene expression in the developing spore (11) .
  • the processing of pro- ⁇ E into ⁇ E which is responsible for gene expression in the mother cell, is also blocked by nonsense mutations in spoIIAC (11) .
  • the deletion of the spoIIAC gene could possibly lead to total disruption of development in the spore and blockage of mother cell development, which is dependent on ⁇ E .
  • the present invention provides a process for the production of a translocated polypeptide comprising i) cultivating a bacterium of the genus Bacillus which is incapable of sporulation due to a mutation, said bac ⁇ terium comprising DNA constructs encoding polypeptides involved in the production of said metabolite under conditions conducive to the expression of said DNA constructs and production of said metabolite, and ii) recovering said metabolite, with the proviso that said bacterium does not belong to the species B. subtilis.
  • the invention furthermore provides host bacteria of the genus Bacillus which is incapable of sporulation due to a mutation, and a method for producing such hosts.
  • the method is based on the use of information provided from B. subtilis to enable the deletion of one or more genes involved in the sporulation process.
  • a deletion of the spoIIAC gene was prepared in vi tro using the splicing by overlap extension technique. This gene was introdu ⁇ ced into Bacillus licheniformis in a temperature sensitive plasmid and, following integration and excision from the chromosome, a precisely located deletion of the chromosomal gene was prepared.
  • the mutated bacterium was totally asporogenous and formed abor ⁇ tively disporic cells characterized by asymmetric septa at the poles of the cell.
  • alkaline protease was the same in batch cul ⁇ tures of the mutant and parent during prolonged incubation for 72 h, but ⁇ -amylase yields were reduced by about 30% by the mutation.
  • the invention has been exemplified in B. licheniformis, but it is envisaged that the invention can be used in other Bacilli as well, such as B. lentus, B. amyloliquefaciens, B. thuringiensis, B. alcalophilus , B. mesentericus, etc.
  • Table I shows the excision frequency of pE194ts carrying the deleted SpoIIAC allele of Bacillus licheniformis
  • Figure 1 shows the splicing by overlap extension reaction used to create the deletion in spoIIA.
  • Figure 2 shows the integration and excision reactions resulting in the production of a deletion in spoIIAC.
  • Figure 4 shows the growth, sporulation and extracellular enzyme synthesis in B. licheniformis DN286 and DN286 spoIIACD3.
  • a and B growth ( ⁇ ) and spores (D) of strain DN286 and growth of DN286 spoIIACD3 (•) in minimal medium and brain heart infusion respectively.
  • C and D serine protease synthesis by strain DN286 ( ⁇ ) and strain DN286 spoIIACD3 (•) in minimal medium and brain heart infusion respectively.
  • E amylase synthesis in strain DN286 (D) and in DN286 spoIIACD3 (0) , in minimal medium (D, 0) and in brain heart infusion ( ⁇ , •).
  • the invention provides a process for the production of a translocated polypeptide comprising i) cultivating a bacterium of the genus Bacillus which is incapable of sporulation due to a mutation, said bac ⁇ terium comprising DNA constructs encoding polypeptides involved in the production of said metabolite under conditions conducive to the expression of said DNA constructs and production of said metabolite, and ii) recovering said metabolite, with the proviso that said bacterium does not belong to the species B. subtilis .
  • the bacterium belongs to the group of species comprising B. licheniformis, B. lentus, B. amyloliquefaciens, B. thuringiensis, etc.
  • the process of the invention has been exemplified by use of a Bacill us that has been made incapable of sporulation through a deletion of the SpoIIAC gene, but any other mutation effectively disrupting the sporulation process in an irrever ⁇ sible manner, such as the Spo2-mutation, and the Spo3-mutation is also comprised within the invention.
  • the process of the invention should preferably make use of a bacterium wherein said mutation is irreversible.
  • the process of the invention is contemplated to be used primarily for the production of any polypeptide, especially translocated polypeptides.
  • Said polypeptide may be endogenous to the bacterium or exoge ⁇ nous, meaning that the polypeptide originally was produced by itself or some other organism, respectively.
  • the sporulation deficient strains of the invention can be used for the production of secondary metabolites.
  • the products from the process of the invention are preferably enzymes, especially industrial enzymes, such as proteases, lipases, cellulases, oxidoreductases, amylases, etc.
  • translocated polypeptide is intended to indicate that the polypeptide expressed carries a signal sequence which enables it to be translocated across the cell membrane.
  • the translocated polypeptide may be a secreted polypeptide or a polypeptide involved in the secretory machi ⁇ nery of the Bacillus cell in question.
  • the present invention also provides a method of producing a bacterium belonging to the genus Bacillus which is incapable of sporulation due to a mutation whereby one or more genes involved in the sporulation process is deleted in part or completely.
  • Gene integration and excision is a common procedure for pro ⁇ ducing specific mutations in B. subtilis and other gram positive bacteria (10, 24, 25) .
  • it is also an efficient procedure for introducing defined mutations into the chromosome of other Bacillus, such as B. licheniformis.
  • B. subtilis Given the close relationship between B. subtilis and B. licheniformis (26) , it was of interest to examine the possibility of using heterologous alleles for the introduction of genes into the chromosome In this way it is according to the invention possible to use the large number of sequenced genes from B. subtilis for genome manipulation in other Bacillus, such as B. licheniformis . Homology was sufficient for integration of the spoIIAC allele of B. licheniformis into the B. subtilis chromosome, albeit at lower frequency than the homologous reaction, and integration presumably occurred at the correct site since these integrants were asporogenous.
  • B. licheniformis It seems likely that the reverse situation would pertain in B. licheniformis; and B. subtilis genes forced into the B. licheniformis chromosome would excise perfectly.
  • amyE is subject to far fewer regulatory genes in B. subtilis than aprE. Catabolite repression and the DegSU systems are the major control systems for this gene (12), although sen (28) and pai (29) are also involved. It is not readily apparent why the synthesis of amylase was affected by the spoIIAC mutation.
  • One of the major aims of the invention is to provide a bacterium suitable for industrial enzyme production purposes.
  • the mutant described here is totally asporogenous under laboratory conditions and the molecular biology of sporulation predicts that it should be unable to produce endospores.
  • the likelihood of reversion of a deletion spanning almost 400 bp is minimal and there is no evidence that suppression may be a problem.
  • the bacterium is equivalent to its parent in e. g. alkaline protease synthesis.
  • DN286 is a Bacillus licheniformis wild type strain
  • NCIMB 6346 B. licheniformis NCIMB 6346 is available from NCIMB.
  • Bacillus subtilis 168 was obtained from D. A. Smith (University of Birmingham, UK) .
  • Escherichia coli M83 was used for all plasmid constructions.
  • Luria broth and Luria broth agar (16) were used routinely with appropriate antibiotic selections; ampicillin (100 mg/ml) and erythromycin (1 mg/ml).
  • Spizizen's minimal salts medium (16), Schaefer's sporulation medium (16) and brain heart infusion (BHI) broth (Oxoid) were also used. Incubation was at 37°C unless otherwise stated.
  • Plasmids Plasmid pUC19 was used for cloning in E. coli JM83.
  • pE194ts a mutant of pE194 which is temperature sensitive for replication was a gift from P. Youngman (University of Georgia, Athens, Ga, USA) .
  • Amylase was assayed in culture supernatants using Phadebas amylase substrate (Pharmacia) at 37°C and converted to release of reducing sugars (maltose) from soluble starch using a stan- dard curve constructed with dilutions of amylase assayed by the Phadebas and Nelson-Somogyi reducing sugar assay. Units are mM maltose equivalents released/min/ml supernatant. All batch cultures were conducted at least twice; figures presented are representative of reproducible patterns of results.
  • the splicing by overlap extension (SOE) reaction was used (19) .
  • the promoter proximal region of the spoIIAC gene was amplified in a reaction with primers A (SEQ ID NO. 2) ;
  • primers A and D represent EcoRI and BamHI sites respectively.
  • the reaction mixtures comprised 200 ng of template DNA (cloned spoIIA operon of B. licheniformis) , 100 pmol of each primer, a final concentration of 125 mM for each dNTP, 6 ml of MgCl 2 (25 mM) , 10 ml of (xlO) Taq Buffer, and sterile Millipore water to 100 ml.
  • the amplification programme consisted of an initial cycle of denaturation at 95°C for 10 min after which 1 unit of Taq poly ⁇ merase (Promega) was added and the reaction mixture was covered with 100 ml of light mineral oil. This was followed by 35 cycles of denaturation at 95°C for 2 min, annealing at 55°C for 2 min, and extension at 72°C for 3 min. An additional cycle of 95°C/2 min, 55°C/2 min and an extension step of 72°C/6 min completed the program.
  • the 464 and 382 bp PCR products were concentrated by ethanol precipitation, purified using the Gene-Clean kit and used as a template (each at 300 ng) with primers A and D in the SOE reac ⁇ tion (same conditions as above) to generate the 806 base-pair spoIIAC deletion comprising fragment AD (Fig. 1) .
  • Fragment AD was cloned into pUC19 through the BamHI and EcoRI restriction sites contained in primers A and D, respectively, transformed into E. coli JM83 and colonies containing plasmid with inserts screened on LB ampicillin plates containing 40 mg/ml X-gal.
  • Recombinant plasmid from a clone was then ligated to pE194ts through the unique Pstl sites in each replicon after treating the former with calf intestinal alkaline phosphatase.
  • Ligation mixes were transformed into E. coli M83 and the recombinants detected by agarose gel electrophoresis of mini-preparations.
  • Plasmid prepared from E. coli was then used to transform pro ⁇ toplasts of B. licheniformis DN286 (10) and competent cells of B. subtilis 168 (20, 7) .
  • B. licheniformis and B. subtilis containing the pE194-based deleted spoIIAC allele were grown overnight in 50 ml LB broth containing erythromycin at 28°C. Samples were diluted and mixed with 3 ml of soft agar containing erythromycin and overlaid onto LB agar Em plates and incubated at 28°C (permissive for replication) and 40°C (non-permissive) . The frequency of integration was the ratio of the number of colonies growing at the permissive to those growing at the non-permissive temperature. Integrants isolated at 40°C were subsequently grown routinely at 37°C.
  • Excision of integrated plasmid was achieved by growing cells at 30°C in LB broth without antibiotic selection. Diluted samples were plated on LB agar and incubated overnight at 37°C and colonies replica plated onto LB agar with and without erythromycin. The frequency of excision was determined as the ratio of total number of colonies to the number of Em r colonies.
  • a deletion in the spoIIAC gene of B. licheniformis was prepared using the splicing by overlap extension (SOE) technique. Two independent PCR amplifications were made from the cloned spoIIA operon using the primers described in Materials and Methods.
  • One product (AB) comprised the distal end of the downstream gene (spoIIAB) and the proximal region of the spoIIAC gene.
  • the second product (CD) covered the distal region of spoIIAC and part of the upstream non-coding region.
  • the extensive regions of homology (overlap) in primers B and C were used to initiate a third PCR amplification which comprised products AB and CD and incorporated primers A and D. This resulted in a fragment containing the ends of the spoIIAC gene encompassing a deletion of 372 bp (fragment AD, see Fig. 1) .
  • Fragment AD was cloned into pUC19 and ligated to pE194ts through the unique Pstl sites in each replicon to produce the shuttle plasmid pHWM2 (Fig. 2) which was transformed into E. coli .
  • Plasmid prepared from E. coli was then used to transform protoplasts of B. licheniformis DN286 and competent cells of B. subtilis 168. Clones from each transformation were verified to contain pHWM2 by restriction enzyme analysis and used for inte ⁇ gration and excision studies.
  • B. licheniformis and B. subtilis cells containing pHWM2 were grown overnight at 28°C and plated onto selective (Em-contai ⁇ ning) and non-selective media and incubated at 45°C.
  • the inte ⁇ gration frequency which was estimated as the proportion of cells which could grow on erythromycin plates at 45°C, for B. licheniformis was about 10 "4 and for B. subtilis (containing the B. licheniformis allele) 100-fold lower (Table 1) .
  • the frequency was between IO "2 and IO "3 for B. licheniformis .
  • a deletion strain from B. licheniformis integrant 3 (Table 1) was chosen for further study. Hybridization of a labelled spoIIA operon from B. licheniformis to Southern blotted chromosomal DNA from the wild type and deleted strains which had been cut with EcoRI, revealed a smaller hybridizing fragment of 3.8 kb in the mutant compared with 4.2 kb in the parent (data not shown) . PCR amplification from chromosomal DNA of the mutant and parent strains using primers A and D showed that the mutant possessed a deletion of about 370 bp. When the 5 PCR product from the mutant was sequenced, a deletion located precisely at the junction point between primers B and C was revealed (Fig. IB) .
  • the naturally low sporulation rate of DN286 was confirmed by comparing with B. licheniformis NCIMB 6346 which showed 90% to 20100% sporulation under the same three conditions.
  • mutant strain showed some minor differences from the parent in the amounts of extracellular enzyme synthesized.
  • hydrolysis zones from ⁇ -1, 3-glucanase and carboxymethyl cellulase were reduced in the mutant compared with the parent strain but synthesis of a-amylase, DN'ase, polygalacturonate lyase, protease, RN'ase and xylanase was largely unaffected.
  • the mutant and its parent were grown in rich (BHI) and minimal media for 72 h. Sporulation and the synthesis of serine protease were monitored (Fig. 4) . Protease production was similar in both parent and mutant. In minimal medium, enzyme yield peaked after incubation for about 40 h in both strains and then remained steady. In BHI, enzyme yield was slightly repressed and peaked after incubation for about 48 h in both strains. The subsequent decline in enzyme yield was less pronounced in BHI than in the salts medium. In both media, the yield of serine protease was unaffected by the spoIIAC deletion.
  • ⁇ -Amylase synthesis consistently initiated later during batch culture of the mutant compared to the parent and consequently these fermentations were continued for a longer time period than those for protease (84 h) .
  • the yield of enzyme from the mutant was about 70% of that obtained from the parent strain.
  • the mutant performed almost as well as the parent, particularly later in the growth cycle when biomass declined in the minimal medium.
  • Bacillus subtilis and other gram-positive bacteria Biochemistry, physiology and molecular genetics. American Society for Microbiology, Washington

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'invention a pour objet un procédé permettant d'obtenir des bactéries du genre Bacillus autre que le B. subtilitis ne pouvant pas sporuler. Ce procédé utilise des informations provenant du B. subtilitis pour assurer la mutation d'une souche parente afin d'obtenir une asporogénicité véritable. Ce type de souches permet de produire des métabolites utiles, et plus particulièrement des polypeptides, comme des enzymes.
PCT/DK1996/000304 1995-07-07 1996-07-04 Production de proteines a l'aide de bacillus incapable de sporuler WO1997003185A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP9505426A JPH11509096A (ja) 1995-07-07 1996-07-04 胞子形成できないバチルスを用いるタンパク質の生産
EP96922780A EP0837925A1 (fr) 1995-07-07 1996-07-04 Production de proteines a l'aide de bacillus incapable de sporuler
AU63538/96A AU6353896A (en) 1995-07-07 1996-07-04 Production of proteins using bacillus incapable of sporulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK80695 1995-07-07
DK0806/95 1995-07-07

Publications (1)

Publication Number Publication Date
WO1997003185A1 true WO1997003185A1 (fr) 1997-01-30

Family

ID=8097796

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1996/000304 WO1997003185A1 (fr) 1995-07-07 1996-07-04 Production de proteines a l'aide de bacillus incapable de sporuler

Country Status (5)

Country Link
EP (1) EP0837925A1 (fr)
JP (1) JPH11509096A (fr)
CN (1) CN1190434A (fr)
AU (1) AU6353896A (fr)
WO (1) WO1997003185A1 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003040352A1 (fr) * 2001-11-06 2003-05-15 Ipsat Therapies Oy Bacillus subtilis non sporule dont des parties du gene codant pour sigma g ont ete eliminees
WO2003087148A2 (fr) * 2002-04-10 2003-10-23 Novozymes A/S Cellule hote de bacille amelioree
WO2004113510A2 (fr) * 2003-06-18 2004-12-29 Dsm Ip Assets B.V. Production de pantothenate au moyen de micro-organismes inaptes a la sporulation
WO2005028659A2 (fr) * 2003-09-22 2005-03-31 Basf Aktiengesellschaft Procede de production d'un complement alimentaire pour animaux contenant de l'acide d-pantothenique et/ou des sels de cet acide
US7270991B2 (en) 2001-07-10 2007-09-18 The Secretary Of State For Defense Expression system
US7895065B2 (en) 2003-02-26 2011-02-22 Sony Corporation Method and apparatus for an itinerary planner
US7981659B2 (en) 2005-10-13 2011-07-19 Kao Corporation Bacillus subtilis mutant strain
CN1878859B (zh) * 2003-11-11 2012-05-30 日下田酱油股份有限公司 新型桥石短小芽孢杆菌和使用该微生物作为宿主生产蛋白的方法
US8894994B2 (en) 2010-05-24 2014-11-25 Synthetic Biologics, Inc. Modified beta-lactamases and methods and uses related thereto
US9290754B2 (en) 2014-04-17 2016-03-22 Synthetic Biologics Inc. Beta-lactamases with improved properties for therapy
US9744221B2 (en) 2014-12-23 2017-08-29 Synthetic Biologics, Inc. Method and compositions for inhibiting or preventing adverse effects of oral antibiotics
US10105322B2 (en) 2014-10-08 2018-10-23 Synthetic Biologics, Inc. Beta-lactamase formulations and uses thereof
US10548955B2 (en) 2015-02-23 2020-02-04 Synthetic Biologics, Inc. Carbapenemases for use with antibiotics for the protection of the intestinal microbiome
US10709773B2 (en) 2015-03-06 2020-07-14 Synthetic Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection
US11034966B2 (en) 2014-08-28 2021-06-15 Synthetic Biologics, Inc. E. coli-based production of beta-lactamase
WO2021224152A1 (fr) 2020-05-05 2021-11-11 Basf Se Amélioration de l'expression dans les processus de fermentation
WO2022269084A1 (fr) 2021-06-24 2022-12-29 Basf Se Cellule hôte de bacillus améliorée avec une protéine rema/remb modifiée
WO2022269082A1 (fr) 2021-06-24 2022-12-29 Basf Se Hôte de production de bacillus amélioré
WO2022269081A1 (fr) 2021-06-24 2022-12-29 Basf Se Cellule hôte de bacillus licheniformis pour la production d'un composé d'intérêt avec une pureté accrue
WO2023117970A1 (fr) 2021-12-20 2023-06-29 Basf Se Procédé de production améliorée de protéines intracellulaires dans bacillus

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108949784B (zh) * 2018-08-06 2020-01-10 齐鲁工业大学 芽孢形成相关基因sigmaF在产酶中的应用
WO2020113365A1 (fr) * 2018-12-03 2020-06-11 清华大学 Bactérie génétiquement modifiée produisant un rendement élevé de lipopeptides et son utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004866A1 (fr) * 1987-11-27 1989-06-01 Celltech Limited Cellules de bacille
EP0369817A2 (fr) * 1988-11-18 1990-05-23 Omnigene Bioproducts, Inc. Souches de bacillus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004866A1 (fr) * 1987-11-27 1989-06-01 Celltech Limited Cellules de bacille
EP0369817A2 (fr) * 1988-11-18 1990-05-23 Omnigene Bioproducts, Inc. Souches de bacillus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DIALOG INFORMATION SERVICES, File 34, SciSearch, Dialog Accession No. 14311191, FLEMING A.B. et al., "Extracellular Enzyme-Synthesis in a Sporulation-Deficient Strain of Bacillus-Licheniformis"; & APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 1995, V61, N11 (Nov), p. 3775-3780. *

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7270991B2 (en) 2001-07-10 2007-09-18 The Secretary Of State For Defense Expression system
WO2003040352A1 (fr) * 2001-11-06 2003-05-15 Ipsat Therapies Oy Bacillus subtilis non sporule dont des parties du gene codant pour sigma g ont ete eliminees
US7319030B2 (en) 2001-11-06 2008-01-15 Ipsat Therapies Oy Non-sporulating Bacillus subtilis having parts of the gene encoding sigma G deleted
WO2003087148A2 (fr) * 2002-04-10 2003-10-23 Novozymes A/S Cellule hote de bacille amelioree
WO2003087148A3 (fr) * 2002-04-10 2004-03-18 Novozymes As Cellule hote de bacille amelioree
US7895065B2 (en) 2003-02-26 2011-02-22 Sony Corporation Method and apparatus for an itinerary planner
WO2004113510A3 (fr) * 2003-06-18 2005-05-26 Dsm Ip Assets Bv Production de pantothenate au moyen de micro-organismes inaptes a la sporulation
WO2004113510A2 (fr) * 2003-06-18 2004-12-29 Dsm Ip Assets B.V. Production de pantothenate au moyen de micro-organismes inaptes a la sporulation
CN1809631B (zh) * 2003-06-18 2010-05-26 帝斯曼知识产权资产管理有限公司 用不能形成芽孢的微生物来生产泛酸盐/酯的方法
WO2005028659A3 (fr) * 2003-09-22 2005-06-23 Basf Ag Procede de production d'un complement alimentaire pour animaux contenant de l'acide d-pantothenique et/ou des sels de cet acide
WO2005028659A2 (fr) * 2003-09-22 2005-03-31 Basf Aktiengesellschaft Procede de production d'un complement alimentaire pour animaux contenant de l'acide d-pantothenique et/ou des sels de cet acide
CN1878859B (zh) * 2003-11-11 2012-05-30 日下田酱油股份有限公司 新型桥石短小芽孢杆菌和使用该微生物作为宿主生产蛋白的方法
US7981659B2 (en) 2005-10-13 2011-07-19 Kao Corporation Bacillus subtilis mutant strain
US8894994B2 (en) 2010-05-24 2014-11-25 Synthetic Biologics, Inc. Modified beta-lactamases and methods and uses related thereto
US9034602B2 (en) 2010-05-24 2015-05-19 Synthetic Biologics, Inc. Modified beta-lactamases and methods and uses related thereto
US11214787B2 (en) 2010-05-24 2022-01-04 Synthetic Biologies, Inc. Modified beta-lactamases and methods and uses related thereto
US9301996B2 (en) 2010-05-24 2016-04-05 Synthetic Biologics, Inc. Modified beta-lactamases and methods and uses related thereto
US9301995B2 (en) 2010-05-24 2016-04-05 Synthetic Biologics, Inc. Modified beta-lactamases and methods and uses related thereto
US10253306B2 (en) 2010-05-24 2019-04-09 Synthetic Biologics, Inc. Modified beta-lactamases and methods and uses related thereto
US10041056B2 (en) 2010-05-24 2018-08-07 Synthetic Biologics, Inc. Modified beta-lactamases and methods and uses related thereto
US9765320B2 (en) 2010-05-24 2017-09-19 Synthetic Biologics, Inc. Modified beta-lactamases and methods and uses related thereto
US9587234B2 (en) 2010-05-24 2017-03-07 Synthetic Biologics, Inc. Modified beta-lactamases and methods and uses related thereto
US9783797B1 (en) 2014-04-17 2017-10-10 Synthetic Biologics, Inc. Beta-lactamases with improved properties for therapy
US10767171B2 (en) 2014-04-17 2020-09-08 Synthetic Biologics, Inc. Beta-lactamases with improved properties for therapy
US9695409B2 (en) 2014-04-17 2017-07-04 Synthetic Biologics, Inc. Beta-lactamases with improved properties for therapy
US9464280B1 (en) 2014-04-17 2016-10-11 Synthetic Biologics, Inc. Beta-lactamases with improved properties for therapy
US10011824B2 (en) 2014-04-17 2018-07-03 Synthetic Biologics, Inc. Beta-lactamases with improved properties for therapy
US9404103B1 (en) 2014-04-17 2016-08-02 Synthetic Biologics, Inc. Beta-lactamases with improved properties for therapy
US11608494B2 (en) 2014-04-17 2023-03-21 Theriva Biologics, Inc. Beta-lactamases with improved properties for therapy
US10087433B1 (en) 2014-04-17 2018-10-02 Synthetic Biologics, Inc. Beta-lactamases with improved properties for therapy
US11236319B2 (en) 2014-04-17 2022-02-01 Synthetic Biologies, Inc. Beta-lactamases with improved properties for therapy
US9376673B1 (en) 2014-04-17 2016-06-28 Synthetic Biologics, Inc. Beta-lactamases with improved properties for therapy
US10336995B2 (en) 2014-04-17 2019-07-02 Synthetic Biologics, Inc. Beta-lactamases with improved properties for therapy
US9290754B2 (en) 2014-04-17 2016-03-22 Synthetic Biologics Inc. Beta-lactamases with improved properties for therapy
US10584326B2 (en) 2014-04-17 2020-03-10 Synthetic Biologics, Inc. Beta-lactamases with improved properties for therapy
US11034966B2 (en) 2014-08-28 2021-06-15 Synthetic Biologics, Inc. E. coli-based production of beta-lactamase
US11542510B2 (en) 2014-08-28 2023-01-03 Synthetic Biologics, Inc. E. coli-based production of beta-lactamase
US11981899B2 (en) 2014-08-28 2024-05-14 Theriva Biologics, Inc. E. coli-based production of beta-lactamase
US10828260B2 (en) 2014-10-08 2020-11-10 Synthetic Biologics, Inc. Beta-lactamase formulations and uses thereof
US10105322B2 (en) 2014-10-08 2018-10-23 Synthetic Biologics, Inc. Beta-lactamase formulations and uses thereof
US10792346B2 (en) 2014-12-23 2020-10-06 Synthetic Biologics, Inc. Method and compositions for inhibiting or preventing adverse effects of oral antibiotics
US9744221B2 (en) 2014-12-23 2017-08-29 Synthetic Biologics, Inc. Method and compositions for inhibiting or preventing adverse effects of oral antibiotics
US11944669B2 (en) 2014-12-23 2024-04-02 Theriva Biologics, Inc. Method and compositions for inhibiting or preventing adverse effects of oral antibiotics
US10046035B2 (en) 2014-12-23 2018-08-14 Synthetic Biologics, Inc. Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics
US11596674B2 (en) 2014-12-23 2023-03-07 Synthetic Biologies, Inc. Method and compositions for inhibiting or preventing adverse effects of oral antibiotics
US11123413B2 (en) 2015-02-23 2021-09-21 Synthetic Biologies, Inc. Carbapenemases for use with antibiotics for the protection of the intestinal microbiome
US10548955B2 (en) 2015-02-23 2020-02-04 Synthetic Biologics, Inc. Carbapenemases for use with antibiotics for the protection of the intestinal microbiome
US11253577B2 (en) 2015-03-06 2022-02-22 Synthetic Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection
US11872268B2 (en) 2015-03-06 2024-01-16 Theriva Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection
US10709773B2 (en) 2015-03-06 2020-07-14 Synthetic Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection
WO2021224152A1 (fr) 2020-05-05 2021-11-11 Basf Se Amélioration de l'expression dans les processus de fermentation
WO2022269082A1 (fr) 2021-06-24 2022-12-29 Basf Se Hôte de production de bacillus amélioré
WO2022269081A1 (fr) 2021-06-24 2022-12-29 Basf Se Cellule hôte de bacillus licheniformis pour la production d'un composé d'intérêt avec une pureté accrue
WO2022269084A1 (fr) 2021-06-24 2022-12-29 Basf Se Cellule hôte de bacillus améliorée avec une protéine rema/remb modifiée
WO2023117970A1 (fr) 2021-12-20 2023-06-29 Basf Se Procédé de production améliorée de protéines intracellulaires dans bacillus

Also Published As

Publication number Publication date
CN1190434A (zh) 1998-08-12
EP0837925A1 (fr) 1998-04-29
JPH11509096A (ja) 1999-08-17
AU6353896A (en) 1997-02-10

Similar Documents

Publication Publication Date Title
EP0837925A1 (fr) Production de proteines a l'aide de bacillus incapable de sporuler
US4469791A (en) Genetically engineered microorganisms for massive production of amylolytic enzymes and process for preparing same
US5217878A (en) Molecular cloning and expression of genes encoding proteolytic enzymes
JP2001514529A (ja) プロテアーゼ活性を有するポリペプチドをコードする核酸
US5958728A (en) Methods for producing polypeptides in mutants of bacillus cells
JP2003519492A (ja) 変異体ａｐｒｅプロモーター
EP0941349B1 (fr) Procedes de production de polypeptides dans des mutants de cellules de bacilles induisant la surfactine
NO300382B1 (no) Transformert prokaryot vertscelle og anvendelse derav
US20120100616A1 (en) Method of double crossover homologous recombination in clostridia
EP2206788B1 (fr) Microorganisme recombinant
US8293516B2 (en) Recombinant microorganism
Fleming et al. Extracellular enzyme synthesis in a sporulation-deficient strain of Bacillus licheniformis
CA2686263C (fr) Systeme d'expression permettant la production de polypeptides sans antibiotiques
FI112666B (fi) Itiöimätön Bacillus subtilis, sen valmistus ja käyttö
EP0414297B1 (fr) Production effective de protéases mutantes
US20220282234A1 (en) Compositions and methods for increased protein production in bacillus lichenformis
JPH11514527A (ja) バキルス エスピー（Ｂａｃｉｌｌｕｓ ｓｐ．）用の陽性選択ベクター
Zaghloul et al. Enhanced alkaline protease production in addition to α-amylase via constructing a Bacillus subtilis strain
Aiba et al. Production of α-Amylase by Bacillus Stearothermophilus (pAT9) and Gene Manipulation to Improve the Stability of the Recombinant Plasmid
Jacobs Cloning of, and studies on, genes coding for subtilisins Carlsberg and BPN'
JPH0616711B2 (ja) 高温で自律増殖するプラスミド

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96195350.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996922780

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1997 505426

Country of ref document: JP

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1996922780

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1996922780

Country of ref document: EP